Strides Shasun receives USFDA approval for Potassium Citrate Extended-Release Tablets

12 Sep 2017 Evaluate

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Potassium Citrate Extended-Release Tablets USP, 5 mEq, 10 mEq, and 15 mEq. According to IMS data, the US market for Potassium Citrate is approximately $110 million.

The company will be the second generic player to commercialize the product. The product, which is the first approval for an Extended Release tablet for the company, will be launched immediately.

Potassium Citrate, a urinary alkalinizing agent, is used for preventing certain types of kidney stones. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals.

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.


Strides Pharma Scien Share Price

882.75 -8.20 (-0.92%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×